


Ask a doctor about a prescription for HIBERIX POWDER AND SOLVENT FOR INJECTABLE SOLUTION
Package Leaflet: Information for the User
Hiberix Powder and Solvent for Solution for Injection
Haemophilus influenzae type b Conjugate Vaccine
Read all of this leaflet carefully before your child is given this vaccine because it contains important information for your child.
Contents of the Package Leaflet
Hiberix is a vaccine used to protect your child against disease caused by Haemophilus influenzaetype b.
Haemophilus influenzaetype b (Hib) can cause meningitis. This can lead to serious problems such as mental retardation, cerebral palsy, deafness, epilepsy, or partial blindness. It can also cause throat inflammation that can lead to death by suffocation. Less frequently, the bacteria can also infect the blood, heart, lungs, bones, joints, and tissues of the eyes and mouth.
Hiberix is indicated for primary vaccination of children from 2 months of age, including those in the following groups:
Hiberix helps your child's body create its own protection (antibodies). This will protect them against the disease.
As with all vaccines, Hiberix may not completely protect all vaccinated children.
Hiberix only protects against infections caused by Haemophilus influenzaetype b, for which the vaccine was developed.
Children with a weakened immune system (due to HIV infection, for example) may not be fully protected by Hiberix.
The vaccine cannot cause the disease it protects your child against.
Hiberix should not be administered
Warnings and precautions
Consult your doctor or pharmacist before your child is given Hiberix if:
A faint may occur before or after any injection, so you should inform your doctor or nurse if your child has fainted after previous injections.
Use of Hiberix with other medicines
Hiberix should not be mixed in the same syringe with other vaccines except with Tritanrix HepB.
Hiberix contains sodium
This medicine contains less than 23 mg (1 mmol) of sodium per 0.5 ml; it is essentially "sodium-free".
Follow exactly the administration instructions for this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
If more Hiberix is administered than should be
No cases of overdose have been reported. Since the package contains only one dose, overdose is unlikely.
If your child misses a dose of Hiberix
Like all medicines, Hiberix can cause side effects, although not everyone gets them.
The side effects that occurred during clinical trials were:
Allergic reactions
As with all injectable vaccines, your child may experience an allergic reaction, although these are very rare (less than 1 in every 10,000 doses of vaccine).
Signs of an allergic reaction may be:
These symptoms usually appear immediately after the injection. Take your child to the doctor immediately if these symptoms start after leaving the clinic.
Seek medical attention immediately if your child has any of the following serious side effects
Very common(may occur in more than 1 in 10 doses of the vaccine):
Common(may occur in up to 1 in 10 doses of the vaccine):
Rare(may occur in up to 1 in 1,000 doses of the vaccine):
Additionally, other effects not observed during clinical trials but reported after marketing of Hiberix are:
Very rare(may occur in less than 1 in 10,000 doses of vaccine):
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website:
www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Composition of Hiberix
Haemophilus influenzaetype b polysaccharide 10 micrograms conjugated with tetanus toxoid as a carrier protein approx. 25 micrograms
Powder: lactose
Solvent: sodium chloride and water for injections
Appearance of the product and contents of the pack
Hiberix is presented as a powder in a glass vial and a solvent in a pre-filled syringe.
The powder is white, and the solvent is clear and colorless.
Marketing authorization holder
GlaxoSmithKline, S.A.
PTM - C/ Severo Ochoa, 2
28760 Tres Cantos
Madrid
Phone: 900 202 700
e-mail: [email protected]
Manufacturer
GlaxoSmithKline Biologicals S.A.
Rue de L’Institut 89; 1330 Rixensart
Belgium
or
SMITHKLINE BEECHAM, S.A.
Ctra. de Ajalvir Km. 2.5 (Alcalá de Henares (Madrid)) – 28806
Spain
Date of the last revision of this leaflet:12/2019
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/.
----------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Before reconstitution or administration, the solvent and the reconstituted vaccine should be visually inspected for any foreign particles and/or changes in physical appearance. If any are observed, do not use the solvent or the reconstituted vaccine.
Instructions for reconstitution of the vaccine with the solvent in a pre-filled syringe
Hiberix should be reconstituted by adding the entire contents of the pre-filled syringe to the vial containing the powder.
To learn how to insert the needle into the syringe, read the instructions provided with images 1 and 2 carefully. However, the syringe provided with Hiberix may be slightly different (without a screw thread) than the syringe in the image. In this case, the needle should be inserted without screwing.

Always hold the syringe by the body, not by the plunger or the Luer adapter, and keep the needle in the axis of the syringe (as shown in image 2). Otherwise, the Luer adapter could become deformed and cause leaks.
If the Luer adapter comes off during syringe assembly, use a new dose of the vaccine (new syringe and vial).
Whether the Luer adapter turns or not, please follow the next steps:
The reconstituted vaccine is a clear to opalescent and colorless solution.
After reconstitution, the vaccine should be administered promptly. If not used within 8 hours after reconstitution, it should be discarded.
Hiberix can be mixed in the same syringe with the monodose vaccine Tritanrix HepB. It should be checked that the vaccine to be mixed with Hiberix is in a monodose package. From the Hiberix packaging, discard the container with the solvent. In this case, the solvent included in the Hiberix packaging will be replaced by the liquid vaccine of Tritanrix HepB. The combined vaccine should be reconstituted by adding the complete contents of the Tritanrix HepB container to the vial containing the white Hib powder. This extemporaneously combined vaccine should be handled in the same way as the reconstituted monocomponent Hiberix vaccine.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for HIBERIX POWDER AND SOLVENT FOR INJECTABLE SOLUTION – subject to medical assessment and local rules.